GlassScriptPhysician profile
Dharmesh H Kaswala
NPI 1639330012
$6,652.07
in general payments reported to CMS, 2019-2025
37 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $225 · 2021: $561 · 2022: $1,257 · 2023: $1,638 · 2024: $1,672 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,346 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,346.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,211.01 | 2020-2025 | |
| Pfizer INC. | $489.69 | 2021-2025 | |
| Janssen Biotech, INC. | $407.23 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $363.43 | 2019-2025 | |
| Madrigal Pharmaceuticals | $337.26 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $324.27 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $299.69 | 2020-2024 | Entyvio, Gattex, Eohilia |
| Astrazeneca Pharmaceuticals LP | $250.00 | 2023-2024 | Farxiga |
| Genzyme Corporation | $233.15 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.04 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $162.62 | 2024-2025 | Voquezna |
| Amgen INC. | $156.26 | 2023-2025 | Otezla, Uplizna |
| Regeneron Healthcare Solutions, INC. | $129.18 | 2023-2025 | Dupixent |
| Viiv Healthcare Company | $124.99 | 2023 | Cabenuva |
| Inari Medical, INC. | $124.81 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $118.05 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $80.94 | 2021-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $77.64 | 2021-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $69.30 | 2022-2023 | Rebyota, Cimzia |
| Cequr Corporation | $54.21 | 2024 | Cequr Simplicity |
| Aimmune Therapeutics, INC. | $47.19 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $47.12 | 2022-2023 | |
| Daiichi Sankyo INC. | $44.71 | 2020-2024 | Injectafer |
| Ardelyx, INC. | $43.72 | 2023-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $43.30 | 2022-2023 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $40.53 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $39.64 | 2021-2023 | Ocaliva |
| Capsovision, INC. | $21.41 | 2023 | Capsocam Plus |
| Vivus LLC | $18.30 | 2025 | Qsymia |
| Novo Nordisk INC | $17.99 | 2025 | Wegovy |
| Albireo Pharma, INC. | $15.96 | 2023 | Bylvay |
| Ipsen Biopharmaceuticals, INC | $14.47 | 2025 | Iqirvo |
| Organon LLC | $14.06 | 2022 | |
| Intra-Sana Laboratories | $13.58 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Curium US LLC | $13.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.08 | 2022 | |
| Evoke Pharma, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmesh Kaswala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.